Ak Medical 2025 revenue reaches RMB 1.482B, up 23.8%, 3D-printed orthopedic implants lead globally

Ak Medical (01789.HK), the Hong Kong-listed orthopedic implant leader, reported 2025 annual results showing total revenue of RMB 1.482 billion, up 10.1% year-on-year, with net profit surging 23.8% to RMB 339 million. The profit growth outpaced revenue due to a higher mix of high-margin overseas sales and digital orthopedics custom products and services, which alone grew 22.8% to RMB 63.04 million. The company operates one of the world's two largest orthopedic implant additive manufacturing bases, and in 2025 added two products to China's NMPA innovative medical device fast-track channel: a magnetically controlled non-invasive extendable prosthesis system and a hip joint component with dual-function osseointegration and antibacterial properties. Ak Medical also received NMPA registration for its K3 surgical robot in May 2025 and the upgraded K3+ in January 2026, the first Chinese total joint arthroplasty robot covering hip, knee, unicompartmental, and revision surgeries. Overseas revenue reached RMB 330 million, up 20.1%, driven by a dual-brand strategy (Ak + JRI) and 15-country regulatory access, with Ak-brand exports posting a 40% CAGR from 2020 to 2025.

This performance places Ak Medical at the center of the medical-dental vertical's most commercially validated AM use case: mass-customized orthopedic implants. Unlike the aerospace qualification grind, where AM success often disappears into supply-chain silence, Ak Medical's model is transparently revenue-generating and scaling. The company's iCOS digital orthopedics platform — spanning AI-assisted 3D modeling, surgical planning, 3D-printed models and guides, custom implants, surgical navigation, and robotics — represents a full-stack digital surgery workflow that directly addresses the reimbursement clarity recently provided by China's National Healthcare Security Administration, which in 2025 issued standardized pricing for medical 3D reconstruction, modeling, guide printing, bioprinting, surgical navigation, and robotics. This policy change is a structural market redefinition event for the medical-dental vertical, enabling hospitals to charge for digital orthopedics services and creating a clear path to commercial adoption. Ak Medical's 5,000+ hospital coverage and 4000+ robotic-assisted surgeries completed position it to capture this emerging revenue stream ahead of domestic and international competitors.

Ak Medical has demonstrated that AM in orthopedics is not a technology experiment but a scalable business with clear unit economics. The company's next execution challenge is converting its 15-country regulatory footprint into sustained revenue growth outside China, particularly in price-sensitive emerging markets where its cost advantage over Western implant makers like Stryker and Zimmer Biomet is most pronounced. For the AM industry, Ak Medical's trajectory confirms that the medical-dental vertical remains the most commercially mature AM application outside consumer electronics, with the added advantage of regulatory barriers that create durable switching costs once implants are qualified in surgical workflows.